0000899243-20-031172.txt : 20201116
0000899243-20-031172.hdr.sgml : 20201116
20201116194654
ACCESSION NUMBER: 0000899243-20-031172
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201112
FILED AS OF DATE: 20201116
DATE AS OF CHANGE: 20201116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sussman Joel F.
CENTRAL INDEX KEY: 0001774297
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39114
FILM NUMBER: 201318965
MAIL ADDRESS:
STREET 1: C/O GALERA THERAPEUTICS, INC.
STREET 2: 2 W LIBERTY BLVD. #110
CITY: MALVERN
STATE: PA
ZIP: 19355
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Galera Therapeutics, Inc.
CENTRAL INDEX KEY: 0001563577
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 461454898
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 WEST LIBERTY BLVD #100
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 610-725-1500
MAIL ADDRESS:
STREET 1: 2 WEST LIBERTY BLVD #100
CITY: MALVERN
STATE: PA
ZIP: 19355
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-12
0
0001563577
Galera Therapeutics, Inc.
GRTX
0001774297
Sussman Joel F.
C/O GALERA THERAPEUTICS, INC.,
2 W LIBERTY BLVD #100
MALVERN
PA
19355
0
1
0
0
Chief Accounting Officer
Common Stock
2020-11-12
4
M
0
10000
1.07
A
10000
D
Common Stock
2020-11-12
4
S
0
10000
10.0627
D
0
D
Common Stock
2020-11-13
4
M
0
3606
1.07
A
3606
D
Common Stock
2020-11-13
4
M
0
3755
1.14
A
7361
D
Common Stock
2020-11-13
4
M
0
2639
2.43
A
10000
D
Common Stock
2020-11-13
4
S
0
10000
10.3197
D
0
D
Stock Option (Right to Buy)
1.07
2020-11-12
4
M
0
10000
0.00
D
2023-01-22
Common Stock
10000
3606
D
Stock Option (Right to Buy)
1.07
2020-11-13
4
M
0
3606
0.00
D
2023-01-22
Common Stock
3606
0
D
Stock Option (Right to Buy)
1.14
2020-11-13
4
M
0
3755
0.00
D
2024-09-16
Common Stock
3755
0
D
Stock Option (Right to Buy)
2.43
2020-11-13
4
M
0
2639
0.00
D
2026-03-01
Common Stock
2639
32238
D
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.00 to $10.25. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.00 to $10.75. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option has fully vested and is currently exercisable.
/s/ Christopher Degnan, Attorney-in-Fact for Joel F. Sussman
2020-11-16